Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
The risk of cancer is decreased by following international health recommendations.
2.
Resection for Early Liver Cancer Tied to Improved Survival.
3.
Healthcare in the Mix in President Biden's Farewell Address
4.
According to new studies, some cancer patients can safely forego radiation therapy.
5.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
1.
The Cutting-Edge of Phlebectomy: Redefining Vein Care
2.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
3.
Ultimate Guide to Oncology Services in the USA
4.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
5.
The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation